An observational study in Covid19 and Kidney Transplantation, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by University Hospital, Strasbourg, France · Observational
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general population and good short-term tolerance. The efficacy of these vaccines ranges from 62 to 95%, which is particularly remarkable, especially for mRNA vaccines. Nevertheless, these studies do not report the vaccine response in organ transplant patients.
It is known that transplant patients have lower vaccine responses than immunocompetent patients due to some degree of immunosuppression.
Therefore, the investigators are interested in evaluating the vaccine response of organ transplant recipients after vaccination against SARS- CoV-2. For non-responder patients, new strategies can be proposed: 3rd or 4th boost of vaccine or perfusion/injection of antiS monoclonal antibodies. These strategies must be evaluated.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 3,500 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Kidney transplant recipients followed in French transplant centers
Exclusion Criteria:
Percentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies
Time frame: One month after the 2nd injection of the COVID-19 vaccine
Compare the seroconversion between different vaccines
Time frame: At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine
Percentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies
Time frame: At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine and at Month 1 after the 3rd and 4th injection.
Describe the patients characteristics associated with seroconversion
Time frame: At Month 24 after the 2nd injection of the COVID-19 vaccine
Assess the tolerance of the 3rd and 4th doses of vaccine in transplant patients
Time frame: At the day of injection, Month 1, Month 2, Month 3, Month 6 and Month 12 post injection
Percentage of patients who develop a Seroconversion for SARS Cov-2 anti Spike and anti N antibodies after injection of monoclonal antibodies
Time frame: At Month 1, Week 6, Week 8, Month 3, Month 6 and Month 12 afin injection of monoclonal antibodies
This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France